Literature DB >> 8495803

Hyperglycemic pseudohypoxia and diabetic complications.

J R Williamson1, K Chang, M Frangos, K S Hasan, Y Ido, T Kawamura, J R Nyengaard, M van den Enden, C Kilo, R G Tilton.   

Abstract

Vasodilation and increased blood flow are characteristic early vascular responses to acute hyperglycemia and tissue hypoxia. In hypoxic tissues these vascular changes are linked to metabolic imbalances associated with impaired oxidation of NADH to NAD+ and the resulting increased ratio of NADH/NAD+. In hyperglycemic tissues these vascular changes also are linked to an increased ratio of NADH/NAD+, in this case because of an increased rate of reduction of NAD+ to NADH. Several lines of evidence support the likelihood that the increased cytosolic ratio of free NADH/NAD+ caused by hyperglycemia, referred to as pseudohypoxia because tissue partial pressure oxygen is normal, is a characteristic feature of poorly controlled diabetes that mimics the effects of true hypoxia on vascular and neural function and plays an important role in the pathogenesis of diabetic complications. These effects of hypoxia and hyperglycemia-induced pseudohypoxia on vascular and neural function are mediated by a branching cascade of imbalances in lipid metabolism, increased production of superoxide anion, and possibly increased nitric oxide formation.

Entities:  

Mesh:

Year:  1993        PMID: 8495803     DOI: 10.2337/diab.42.6.801

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  208 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  Transition metals redox: reviving an old plot for diabetic vascular disease.

Authors:  V M Monnier
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Alterations in enzymatic antioxidant defence in diabetes mellitus--a rational approach.

Authors:  E Szaleczky; J Prechl; J Fehér; A Somogyi
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

4.  Effect of Tungstate Administration on the Lipid Peroxidation and Antioxidant Parameters in Salivary Glands of STZ-Induced Diabetic Rats.

Authors:  Douglas Nesadal de Souza; Eugen Mendes Nesadal de Souza; Marlus da Silva Pedrosa; Fernando Neves Nogueira; Alyne Simões; José Nicolau
Journal:  Biol Trace Elem Res       Date:  2020-06-29       Impact factor: 3.738

Review 5.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

6.  Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation.

Authors:  Peng Zhang; Kuiyi Xing; James Randazzo; Karen Blessing; Marjorie F Lou; Peter F Kador
Journal:  Exp Eye Res       Date:  2012-06-15       Impact factor: 3.467

Review 7.  Oxidative stress in diabetic nephropathy.

Authors:  N Kashihara; Y Haruna; V K Kondeti; Y S Kanwar
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

8.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

9.  Reduction of Glut1 in the Neural Retina But Not the RPE Alleviates Polyol Accumulation and Normalizes Early Characteristics of Diabetic Retinopathy.

Authors:  Nicholas C Holoman; Jacob J Aiello; Timothy D Trobenter; Matthew J Tarchick; Michael R Kozlowski; Emily R Makowski; Darryl C De Vivo; Charandeep Singh; Jonathan E Sears; Ivy S Samuels
Journal:  J Neurosci       Date:  2021-02-23       Impact factor: 6.167

Review 10.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.